

CLAIMS

What is claimed is:

- 5 1. An implantable cardiac lead system, comprising:
 a cardiac lead; and
 a sleeve arrangement provided on the lead, the sleeve arrangement
comprising:
 one or more first locations comprising a first material that
10 substantially prevents tissue in-growth between the first locations and cardiac tissue
 contacting the first locations; and
 one or more adhesion sites provided at the one or more first
 locations, the adhesion sites promoting tissue in-growth or attachment between the
 adhesion sites and cardiac tissue contacting the adhesion sites.
- 15 2. The system of claim 1, wherein the cardiac lead comprises one or more
 electrodes.
- 20 3. The system of claim 2, wherein the one or more electrodes comprise one
 or more of sensing, pacing, or shocking electrodes.
4. The system of claim 1, wherein the cardiac lead comprises one or more
 sensors.
- 25 5. The system of claim 4, wherein the one or more sensors comprise one or
 more of an accelerometer, pressure sensor, oxygen sensor, or temperature sensor.
6. The system of claim 1, wherein the lead system further comprises a drug
 delivery mechanism.
- 30

7. The system of claim 1, wherein the adhesion sites define apertures in the sleeve at the one or more first locations of the sleeve.

8. The system of claim 1, wherein the adhesion sites comprise a material that promotes cardiac tissue in-growth or attachment at the adhesion sites.

9. The system of claim 1, wherein the adhesion sites comprise exposed portions of the one or more electrodes.

10. The system of claim 1, wherein the adhesion sites comprise a structure having a porous surface that promotes cardiac tissue in-growth or attachment at the adhesion sites.

11. The system of claim 10, wherein the structure comprises a metallic annular structure.

12. The system of claim 1, wherein the first material comprises a first polymer material that substantially prevents tissue in-growth between the first locations and cardiac tissue contacting the first locations, and the adhesion sites comprise a second polymer material that promotes tissue in-growth or attachment between the adhesion sites and cardiac tissue contacting the adhesion sites.

13. The system of claim 12, wherein the second polymer material has a porosity differing from that of the first polymer material.

14. The system of claim 12, wherein the second polymer material has an average pore size differing from that of the first polymer material.

15. The system of claim 12, wherein the second polymer material has a distribution of pore sizes differing from that of the first polymer material.

16. The system of claim 12, wherein the second polymer material has a hydrophobicity differing from that of the first polymer material.

5 17. The system of claim 1, wherein the first material comprises a first type of PTFE, and a second material of the adhesion sites comprises a second type of PTFE.

10 18. The system of claim 1, wherein the first material comprises a first type of ePTFE, and a second material of the adhesion sites comprises a second type of ePTFE.

19. The system of claim 1, wherein the lead further comprises a bias mechanism proximate one or more of the adhesion sites.

15 20. The system of claim 19, wherein the bias mechanism comprises a biased coil electrode, a biased insulation material disposed on an outer layer of the lead, a biased structure operatively coupled to a lumen defined within the lead or a biased structure disposed on the outer layer of the lead.

TOPTF" 804000T

10040001
15
2040001
20

26. The system of claim 21, wherein:

the first fixation arrangement comprises a spiraled portion of the lead; and
the second fixation arrangement comprises one or more adhesion sites

provided with the sleeve for promoting coronary sinus tissue in-growth or attachment at
the adhesion sites.

27. The system of claim 26, wherein the adhesion sites define apertures in
the sleeve.

28. The system of claim 26, wherein the adhesion sites comprise a material
that promotes coronary sinus tissue in-growth or attachment at the adhesion sites.

29. The system of claim 26, wherein the adhesion sites comprise one or more
exposed portions of the electrode.

30. The system of claim 26, wherein the adhesion sites comprise a porous
surface structure having one or more of a porosity, pore sizes, or pore size distribution
that promotes coronary sinus tissue in-growth or attachment at the adhesion sites.

31. An implantable cardiac lead system, comprising:
a lead comprising a electrode;
a first fixation arrangement comprising a spiraled portion of the lead that
provides a first fixation mechanism between the lead and coronary sinus tissue; and
a second fixation arrangement that provides a second fixation mechanism
between the lead and coronary sinus tissue, the second fixation arrangement
comprising a polymer sleeve arrangement encompassing all or a portion of the
electrode, the polymer sleeve arrangement comprising one or more adhesion sites for
promoting coronary sinus tissue in-growth or attachment at the adhesion sites.

32. The system of claim 31, wherein the one or more adhesion sites of the polymer sleeve arrangement comprise a first material that promotes coronary sinus tissue in-growth or attachment at the adhesion sites.

5 33. The system of claim 31, wherein:
the polymer sleeve arrangement, other than at the one or more adhesion sites, comprises a first material that prevents coronary sinus tissue in-growth; and
the one or more adhesion sites comprise a second material that promotes coronary sinus tissue in-growth or attachment at the adhesion sites.

10 34. The system of claim 33, wherein the second material comprises a type of PTFE that promotes coronary sinus tissue in-growth or attachment.

15 35. The system of claim 33, wherein the second material comprises a type of ePTFE that promotes coronary sinus tissue in-growth or attachment.

20 36. The system of claim 33, wherein the first material comprises a type of PTFE or ePTFE that prevents coronary sinus tissue in-growth.

25 37. The system of claim 31, wherein the one or more adhesion sites of the polymer sleeve arrangement comprises one or more partial or complete gaps provided on the polymer sleeve arrangement.

30 38. The system of claim 37, wherein the gaps comprise between about 1 percent and about 10 percent of a surface area of the polymer sleeve arrangement.

35 39. The system of claim 37, wherein the gaps comprise a circumferential dimension and a longitudinal dimension, the circumferential dimension being greater than the longitudinal dimension.

47. The method of claim 43, wherein promoting tissue in-growth or attachment comprises promoting tissue in-growth or attachment via apertures defined at the adhesion sites.

5

48. The method of claim 43, wherein promoting tissue in-growth or attachment comprises promoting tissue in-growth or attachment using a material that promotes cardiac tissue in-growth or attachment at the adhesion sites.

10

49. The method of claim 43, wherein promoting tissue in-growth or attachment comprises promoting tissue in-growth or attachment using one or more exposed portions of the one or more electrodes.

15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995

50. The method of claim 43, wherein promoting tissue in-growth or attachment comprises promoting tissue in-growth or attachment using a porous surface structure having one or more of a porosity, pore sizes or distribution of pore sizes that promote cardiac tissue in-growth or attachment at the adhesion sites.

51. The method of claim 43, wherein the first material comprises a first polymer material that substantially prevents tissue in-growth between the first locations and cardiac tissue contacting the first locations, and promoting tissue in-growth or attachment comprises promoting tissue in-growth or attachment using a second polymer material at the adhesion sites that promotes tissue in-growth or attachment between the adhesion sites and cardiac tissue contacting the adhesion sites.

25

52. The method of claim 43, wherein a second material is disposed at the adhesions sites, the method further comprising varying one or more of a porosity, pore sizes or distribution of pore sizes of the second material to be different from that of the first polymer material.

30

53. The method of claim 43, further comprising generating a bias force at or proximate one or more of the adhesion sites.

54. A method of stabilizing a lead passing into a coronary sinus of a heart,

comprising:

providing a lead comprising at least one electrode;

stabilizing the lead at a first fixation location within a right atrium of the heart or a proximal portion of the coronary sinus; and

stabilizing the lead at a second fixation location within a distal portion of the coronary sinus.

55. The method of claim 54, wherein:

stabilizing the lead at the first fixation location comprises mechanically stabilizing the lead at the first fixation location; and

stabilizing the lead at the second fixation location comprises mechanically stabilizing the lead at the second fixation location.

56. The method of claim 55, wherein mechanically stabilizing the lead comprises using a spiraled portion of the lead at one of the first or second fixation locations to stabilize the lead.

57. The method of claim 55, wherein mechanically stabilizing the lead comprises using a first spiraled portion of the lead at the first fixation location and using a second spiraled portion of the lead at the second fixation location to stabilize the lead.

FOR OFFICIAL USE ONLY

58. The method of claim 54, wherein:

stabilizing the lead at the first fixation location comprises mechanically
stabilizing the lead at the first fixation location; and

5 stabilizing the lead at the second fixation location comprises stabilizing the
lead at the second fixation location using cellular adhesion at selected portions of
coronary sinus vasculature.

59. The method of claim 54, wherein:

10 stabilizing the lead at the first fixation location comprises stabilizing the
lead at the first fixation location using cellular adhesion at the first fixation location; and
stabilizing the lead at the second fixation location comprises mechanically
stabilizing the lead at the second fixation location.

15 60. The method of claim 54, further comprising delivering a drug using the
lead.